Peptides / Brain and mood

Small molecule · 318.4 Da

Noopept (omberacetam)

Approved in RussiaNot banned in sport

Noopept, also called omberacetam, is a small molecule derived from a dipeptide and approved in Russia as a nootropic tablet. Most studies are in animals, on memory and brain protection, with a few small studies in people on brain activity. PepBank shows 18 results on Noopept from 5 studies in people, and 298 from animal and lab studies. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.

Also known as GVS-111, GVS111, Omberacetam, Noopept, Ноопепт

Small molecule, shown without its saltPubChem 180496

Evidence level: Mostly animal studies298 of 316 results come from studies in animals and lab cells. 5 studies in people.

Results in people

6% of 316 results

Results in animals

215

68% of 316 results

Results in lab cells

26% of 316 results

From computer models

0% of 316 results

Overview

Noopept (omberacetam) at a glance

What it is	Small molecule
Approval	Approved in Russia only (registered as Noopept / Ноопепт)
In sport	Not listed as banned by WADA
Studies	85 studies with results. 80 of them gave Noopept, with 316 results. 18 in people215 in animals83 in lab cells
Best study in people	Non-randomized trial with 30 people (2009)
Clinical trials	None registered
Community use	Cognitive enhancement

The science

What is Noopept?

A defined dipeptide-derived small molecule, also called omberacetam or GVS-111. Russia registers Noopept tablets as a nootropic drug.

316

Study results in PepBank

Noopept (omberacetam) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Noopept (omberacetam) is a small molecule, not a peptide chain.

Formula

C₁₇H₂₂N₂O₄

Molecular weight

318.4 g/mol

CAS number

157115-85-0

Development

AO Otisipharm Pro (holder of the current registration, per a copy of the State Register of Medicines, pharmcontrol.ru, register data of 2026-10-02). Pharmstandard-Leksredstva or Otisipharm Pro (label manufacturers). ZAO LEKKO held the earlier registration LS-001577. Highest phase: past the trial stage (see status).

Identifiers

PubChem 180496, ChEMBL CHEMBL4303687, UNII 4QBJ98683M

SMILES and InChIKey

InChIKey
PJNSMUBMSNAEEN-AWEZNQCLSA-N

SMILES
CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CC2=CC=CC=C2

See charge, composition and 3D structure on the Scientific page

The evidence

What Noopept studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies298 of 316 results come from studies in animals and lab cells. 5 studies in people.

Brain and nerves

58 results · 7 in people · 29 animal · 22 lab

In patients with posttraumatic or vascular brain disorders, Noopept increased alpha-rhythm power on EEG. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008

Top results

In patients with posttraumatic or vascular brain disorders, Noopept increased alpha-rhythm power on EEG. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008)
In patients with tuberculosis, Noopept added to treatment promoted normal autonomic nervous system function. (Klinicheskaia meditsina, 2009)
In diabetic rats, noopept reduced the loss of glutathione peroxidase compared with untreated diabetes. (Molecular neurobiology, 2021)

Memory and thinking

53 results · 2 in people · 50 animal · 1 lab

In patients with stroke, noopept improved cognitive test results after 2 months compared with controls. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011

Top results

In patients with stroke, noopept improved cognitive test results after 2 months compared with controls. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011)
In patients with stroke, the global assessment showed mild improvement with Noopept and no change in controls. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011)
In mice with removed olfactory bulbs, Noopept restored spatial memory. (Journal of psychopharmacology, 2007)

Mood, stress and behavior

20 results · 2 in people · 18 animal

In patients with tuberculosis, Noopept added to treatment reduced anxiety symptoms. Klinicheskaia meditsina, 2009

Top results

In patients with tuberculosis, Noopept added to treatment reduced anxiety symptoms. (Klinicheskaia meditsina, 2009)
In adult female rats, early noopept injections did not affect plus maze behavior. (Eksperimental'naia i klinicheskaia farmakologiia, 2005)
In healthy volunteers, noopept improved psychological functional state in cold and hot climates. (Eksperimental'naia i klinicheskaia farmakologiia, 2007)

Cells, genes and aging

13 results · 1 in people · 9 animal · 3 lab

In patients with tuberculosis, Noopept added to treatment promoted normal antioxidant function. Klinicheskaia meditsina, 2009

Top results

In patients with tuberculosis, Noopept added to treatment promoted normal antioxidant function. (Klinicheskaia meditsina, 2009)
In rats, GVS-111 reduced brain diene conjugate accumulation during immobilization. (Eksperimental'naia i klinicheskaia farmakologiia, 1997)
In diabetic rats, noopept reduced mitochondrial free oxygen radicals in nerve tissues compared with untreated diabetes. (Molecular neurobiology, 2021)

Daily life and fitness

4 results · 1 in people · 3 animal

In healthy volunteers, noopept increased physical work capacity in a hot climate. Eksperimental'naia i klinicheskaia farmakologiia, 2007

Top results

In healthy volunteers, noopept increased physical work capacity in a hot climate. (Eksperimental'naia i klinicheskaia farmakologiia, 2007)
In rats, noopept reduced horizontal activity compared with saline controls. (Eksperimental'naia i klinicheskaia farmakologiia, 2005)
In animals after ketamine anesthesia, intranasal Noopept increased activity. (Georgian medical news, 2019)

Immune system and inflammation

24 results · 22 animal · 2 lab

In mice with removed olfactory bulbs, Noopept increased blood antibodies to amyloid peptide oligomers. Journal of psychopharmacology, 2007

Top results

In mice with removed olfactory bulbs, Noopept increased blood antibodies to amyloid peptide oligomers. (Journal of psychopharmacology, 2007)
In rats, Noopept reduced inflammation caused by carrageenan. (Eksperimental'naia i klinicheskaia farmakologiia, 2012)
In mice, noopept increased macrophage activity. (Bulletin of experimental biology and medicine, 2007)

All 5 studies in people

In people

In patients with tuberculosis, Noopept added to treatment promoted normal autonomic nervous system function.

2009Klinicheskaia meditsina30 people

In people

In patients with stroke, noopept improved cognitive test results after 2 months compared with controls.

2011Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

In people

In patients with posttraumatic or vascular brain disorders, Noopept increased alpha-rhythm power on EEG.

2008Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

In people

In healthy volunteers, noopept improved psychological functional state in cold and hot climates.

2007Eksperimental'naia i klinicheskaia farmakologiia

In people

Noopept left the human body more slowly than it left rats and rabbits.

2004Eksperimental'naia i klinicheskaia farmakologiia

All 85 Noopept studies by area Open the Scientific page

Key Noopept studies

Studies in people come first, then studies in animals and in the lab.

People
[Prevention of neuro- and cardiotoxic side effects of tuberculosis chemotherapy with noopept]
Mordyk et al. 2009 · Klinicheskaia meditsina · 30 people · cited by 0
5 results
People
[Noopept in the treatment of mild cognitive impairment in patients with stroke]
Amelin et al. 2011 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · cited by 0
2 results
People
[Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin]
Bochkarev et al. 2008 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · cited by 0
6 results
People
[Meteoadaptogenic properties of peptide drugs in healthy volunteers]
Shabanov et al. 2007 · Eksperimental'naia i klinicheskaia farmakologiia · cited by 0
2 results
People
[Interspecies differences of noopept pharmacokinetics]
Boĭko et al. 2004 · Eksperimental'naia i klinicheskaia farmakologiia · cited by 2
9 results

All 85 Noopept (omberacetam) studies

Noopept clinical trials

ClinicalTrials.gov lists no trial of Noopept. A trial under another name may exist.

Status and safety

Is Noopept approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in Russia only (registered as Noopept / Ноопепт). No FDA approval and no central EU authorisation (EMA). Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Noopept side effects and safety

PepBank has 9 safety results from studies of Noopept. 2 of them come from studies in people.

Safety results from studies (9)

In patients with tuberculosis, Noopept added to treatment reduced neurotoxic reactions to tuberculosis drugs. (Klinicheskaia meditsina, 2009)
In patients with tuberculosis, Noopept added to treatment reduced cardiotoxic reactions to tuberculosis drugs. (Klinicheskaia meditsina, 2009)
In rabbits, chronic noopept caused no irreversible damage in the organs and systems studied. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)
In rabbits, chronic noopept showed no allergenic activity. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)
In rabbits, chronic noopept showed no immune toxicity. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)
In rabbits, chronic noopept showed no mutagenic activity. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)
In animals, noopept did not affect reproductive function. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)
In animals, noopept did not affect offspring development before birth. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)
In animals, noopept did not affect offspring development after birth. (Eksperimental'naia i klinicheskaia farmakologiia, 2002)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
10 mg twice daily	Human	human	Not reported	first month	Trial in people without random groups · n = 30	Mordyk 2009
20 mg daily	Human	human	Not reported	2 months	Trial in people without random groups	Amelin 2011
0.01 mg/kg	Animal	mouse	Not reported	21 days and a further 5 days training	Study in live animals	Ostrovskaya 2007
0.5 mg/kg/day	Animal	rat	intravenous	First dose 1 h after lesion, then 9 post-operative days	Study in live animals	Ostrovskaya 1999
5 mg/kg	Animal	rat	intraperitoneal	1 h	Study in live animals	Gudasheva 1997
0.5 mg/kg	Animal	rat	intraperitoneal	7 days before injury	Study in live animals	Ostrovskaya 2008
20 nM	Animal	rat	intranasal	Not reported	Study in live animals	Dagda 2022
0.2mg/kg	Animal	rats	subcutaneous	Not reported	Study in live animals	Vorobyov 2011
0.5 mg/kg/day	Animal	rat	intraperitoneal	9 days following operation	Study in live animals	Ostrovskaya 1997
5 mg/kg	Animal	rat	oral	Before each toxin injection and 16 days after the streptozotocin course	Study in live animals	Ostrovskaya 2014
0.5 mg/kg/day	Animal	Not reported	Not reported	10 days	Study in live animals	Ostrovskaia 2001
0.5 mg/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Belnik 2007
0.5 mg/kg	Animal	rat	intraperitoneal	14 days	Study in live animals	Gürbüz 2019
0.5 mg/day	Animal	rats	intraperitoneal	28 days	Study in live animals	Ostrovskaia 2010
0.5 mg/kg	Animal	mouse	intraperitoneal	Not reported	Study in live animals	Bel'nik 2009
0.05-0.10 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Uyanaev 2003
0.5-10 mg/kg	Animal	rat	oral	Not reported	Study in live animals	Ostrovskaya 2001
0.12 and 0.5 mg/kg	Animal	rat	intraperitoneal	Single injection 15 or 60 min before immobilization	Study in live animals	Lysenko 1997
0.5 mg/kg	Animal	mouse	intraperitoneal	14 days before and 6, 13, or 14 days after streptozotocin	Study in live animals	Ostrovskaya 2019
1, 5, and 10 mg/kg	Animal	rats	intraperitoneal	single administration	Study in live animals	Alekseeva 2012
5 mg/kg	Animal	mice	intraperitoneal	Not reported	Study in live animals	Alekseeva 2012
0.5 mg/kg	Animal	rat	intraperitoneal	15 min and 2, 24, and 48 h after occlusion	Study in live animals	Gavrilova 2006
0.1 mg/kg daily	Animal	rat	Not reported	Not reported	Study in live animals	Voronina 2005
1 mg/kg intraperitoneally or 10 mg/kg orally, once daily	Animal	Not reported	intraperitoneal or oral	10 days	Study in live animals	Ostrovskaia 2002
single intravenous 0.5 or 5 mg/kg, single oral 10, 50 or 100 mg/kg, or prolonged oral 5 mg/kg	Animal	mouse	intravenous or oral (source also labels intravenous doses p.o.)	single administration or 10 days	Study in live animals	Kovalenko 2002
5 mg/kg	Animal	rat	intravenous	Not reported	Study in live animals	Kovalenko 2002
0.5 mg/kg daily	Animal	rat	intramuscular	25 days	Study in live animals	Kovalenko 2002
5 mg/kg daily	Animal	rat	oral	25 days	Study in live animals	Kovalenko 2002
0.8 mg/kg/day	Animal	rat	intraperitoneal	Not reported	Study in live animals	Romanova 1998
1 mg/kg/day	Animal	mice	Not reported	Not reported	Study in live animals	Kovalev 2014
0.5 mg/kg	Animal	mouse	intraperitoneal	Not reported	Study in live animals	Kravchenko 2009
0.5 mg/kg	Animal	rat	injection	7 days	Study in live animals	Zarubina 2009
0.5 mg/kg	Animal	mouse	intraperitoneal	15 min before learning	Study in live animals	Bel'nik 2007
1 mg/kg	Animal	rat	intraperitoneal	Not reported	Study in live animals	Shabanov 2007
0.01 mg/kg	Animal	mouse	Not reported	21 days	Study in live animals	Bobkova 2005
0.2 mg/kg	Animal	rat	subcutaneous	Not reported	Study in live animals	Kovalev 2002
10 or 100 mg/kg	Animal	rabbit	oral	6 months	Study in live animals	Kovalenko 2002
0.1 mg/kg/day	Animal	rat	intraperitoneal	Not reported	Study in live animals	Inozemtsev 1998
10 nM	Lab	Helix pomatia	Not reported	Not reported	Study on tissue taken from a body	Bukanova 2002
10(-11) to 10(-9) M	Lab	Helix Pomatum	Not reported	Not reported	Study on tissue taken from a body	Ostrovskaia 2001

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

PsychonautWiki reports oral omberacetam use for cognitive effects. The Russian manufacturer label gives separate medicinal regimens.

Reported routines and cautions

What people use it for

Cognitive enhancementS1

Reported regimens

Regimens that community sources report for Noopept (omberacetam). Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
PsychonautWiki common amount	oral	10 to 20 mg per dose	Not stated	Not stated	Single community wiki. Frequency and course length are not specified for this amount.	S1
Russian label initial regimenOfficial label dosing of an approved product	oralThe label specifies sufficient water.	10 mg per dose	twice daily, morning and afternoon	1.5 to 3 months	The current official manufacturer label and a 2015 non-vendor label reprint agree on amount, route, frequency and duration. RLS carries medicine advertisements. These are label copies, not independent clinical evidence.	S4
Russian label conditional increaseOfficial label dosing of an approved product	oralThe label specifies sufficient water.	10 mg per dose	three times daily	1.5 to 3 months	The current official manufacturer label and a 2015 non-vendor label reprint agree on amount, route, frequency and duration. RLS carries medicine advertisements. These are label copies, not independent clinical evidence.	S4

Cautions

PsychonautWiki states that the exact toxic dose is unknown. It states that recreational toxicity and long-term health effects do not seem scientifically studied.S1

Community sources

S1Omberacetam, PsychonautWiki (opens in a new tab)psychonautwiki.org
S3Russian national register search for Noopept (opens in a new tab)grls.rosminzdrav.ru
S4Noopept official-instruction reprint, RLS, manufacturer approval 2015rlsnet.rucarries seller links, not linked

plus 1 seller page (not linked)

Gaps

Community frequency and duration are unspecified. The current manufacturer label and older non-vendor label reprint agree on retained dosing fields. The current national register detail remains unconfirmed.

Questions and more

Ask a question about Noopept

The answer links to every study it uses.

What does the evidence say about Noopept?Is Noopept tested in people?Compare with Cerebrolysin Compare with Semax

Sources

Database: PepBank data for Noopept (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Noopept

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Noopept (omberacetam)

Approved in RussiaNot banned in sport

Also known as GVS-111, GVS111, Omberacetam, Noopept, Ноопепт

What it is

Small molecule

Approval

Approved in Russia only (registered as Noopept / Ноопепт)

In sport

Not listed as banned by WADA

Studies

85 studies with results. 80 of them gave Noopept, with 316 results.
18 in people215 in animals83 in lab cells

Best study in people

Non-randomized trial with 30 people (2009)

Clinical trials

None registered

Community use

Cognitive enhancement

Dose as reported

Class

Species

Route

Duration

Design

Source

10 mg twice daily

Human

human

Not reported

first month

Trial in people without random groups · n = 30

Mordyk 2009

20 mg daily

Human

human

Not reported

2 months

Trial in people without random groups

Amelin 2011

0.01 mg/kg

Animal

mouse

Not reported

21 days and a further 5 days training

Study in live animals

Ostrovskaya 2007

0.5 mg/kg/day

Animal

rat

intravenous

First dose 1 h after lesion, then 9 post-operative days

Study in live animals

Ostrovskaya 1999

5 mg/kg

Animal

rat

intraperitoneal

1 h

Study in live animals

Gudasheva 1997

0.5 mg/kg

Animal

rat

intraperitoneal

7 days before injury

Study in live animals

Ostrovskaya 2008

20 nM

Animal

rat

intranasal

Not reported

Study in live animals

Dagda 2022

0.2mg/kg

Animal

rats

subcutaneous

Not reported

Study in live animals

Vorobyov 2011

0.5 mg/kg/day

Animal

rat

intraperitoneal

9 days following operation

Study in live animals

Ostrovskaya 1997

5 mg/kg

Animal

rat

oral

Before each toxin injection and 16 days after the streptozotocin course

Study in live animals

Ostrovskaya 2014

0.5 mg/kg/day

Animal

Not reported

10 days

Study in live animals

Ostrovskaia 2001

0.5 mg/kg

Animal

mouse

Not reported

Study in live animals

Belnik 2007

0.5 mg/kg

Animal

rat

intraperitoneal

14 days

Study in live animals

Gürbüz 2019

0.5 mg/day

Animal

rats

intraperitoneal

28 days

Study in live animals

Ostrovskaia 2010

0.5 mg/kg

Animal

mouse

intraperitoneal

Not reported

Study in live animals

Bel'nik 2009

0.05-0.10 mg/kg

Animal

rat

Not reported

Study in live animals

Uyanaev 2003

0.5-10 mg/kg

Animal

rat

oral

Not reported

Study in live animals

Ostrovskaya 2001

0.12 and 0.5 mg/kg

Animal

rat

intraperitoneal

Single injection 15 or 60 min before immobilization

Study in live animals

Lysenko 1997

0.5 mg/kg

Animal

mouse

intraperitoneal

14 days before and 6, 13, or 14 days after streptozotocin

Study in live animals

Ostrovskaya 2019

1, 5, and 10 mg/kg

Animal

rats

intraperitoneal

single administration

Study in live animals

Alekseeva 2012

5 mg/kg

Animal

mice

intraperitoneal

Not reported

Study in live animals

Alekseeva 2012

0.5 mg/kg

Animal

rat

intraperitoneal

15 min and 2, 24, and 48 h after occlusion

Study in live animals

Gavrilova 2006

0.1 mg/kg daily

Animal

rat

Not reported

Study in live animals

Voronina 2005

1 mg/kg intraperitoneally or 10 mg/kg orally, once daily

Animal

Not reported

intraperitoneal or oral

10 days

Study in live animals

Ostrovskaia 2002

single intravenous 0.5 or 5 mg/kg, single oral 10, 50 or 100 mg/kg, or prolonged oral 5 mg/kg

Animal

mouse

intravenous or oral (source also labels intravenous doses p.o.)

single administration or 10 days

Study in live animals

Kovalenko 2002

5 mg/kg

Animal

rat

intravenous

Not reported

Study in live animals

Kovalenko 2002

0.5 mg/kg daily

Animal

rat

intramuscular

25 days

Study in live animals

Kovalenko 2002

5 mg/kg daily

Animal

rat

oral

25 days

Study in live animals

Kovalenko 2002

0.8 mg/kg/day

Animal

rat

intraperitoneal

Not reported

Study in live animals

Romanova 1998

1 mg/kg/day

Animal

mice

Not reported

Study in live animals

Kovalev 2014

0.5 mg/kg

Animal

mouse

intraperitoneal

Not reported

Study in live animals

Kravchenko 2009

0.5 mg/kg

Animal

rat

injection

7 days

Study in live animals

Zarubina 2009

0.5 mg/kg

Animal

mouse

intraperitoneal

15 min before learning

Study in live animals

Bel'nik 2007

1 mg/kg

Animal

rat

intraperitoneal

Not reported

Study in live animals

Shabanov 2007

0.01 mg/kg

Animal

mouse

Not reported

21 days

Study in live animals

Bobkova 2005

0.2 mg/kg

Animal

rat

subcutaneous

Not reported

Study in live animals

Kovalev 2002

10 or 100 mg/kg

Animal

rabbit

oral

6 months

Study in live animals

Kovalenko 2002

0.1 mg/kg/day

Animal

rat

intraperitoneal

Not reported

Study in live animals

Inozemtsev 1998

10 nM

Lab

Helix pomatia

Not reported

Study on tissue taken from a body

Bukanova 2002

10(-11) to 10(-9) M

Lab

Helix Pomatum

Not reported

Study on tissue taken from a body

Ostrovskaia 2001

Context

Route

Amount

How often

How long

Agreement

Sources

PsychonautWiki common amount

oral

10 to 20 mg per dose

Not stated

Single community wiki. Frequency and course length are not specified for this amount.

Russian label initial regimenOfficial label dosing of an approved product

oralThe label specifies sufficient water.

10 mg per dose

twice daily, morning and afternoon

1.5 to 3 months

The current official manufacturer label and a 2015 non-vendor label reprint agree on amount, route, frequency and duration. RLS carries medicine advertisements. These are label copies, not independent clinical evidence.

Russian label conditional increaseOfficial label dosing of an approved product

oralThe label specifies sufficient water.

10 mg per dose

three times daily

1.5 to 3 months

Noopept (omberacetam)

Noopept (omberacetam) at a glance

What is Noopept?

Noopept (omberacetam) structure and chemistry

What Noopept studies show

Brain and nerves

Memory and thinking

Mood, stress and behavior

Cells, genes and aging

Daily life and fitness

Immune system and inflammation

All 5 studies in people

Key Noopept studies

Noopept clinical trials

Is Noopept approved?

Noopept side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about Noopept

Related peptides

Sources

Noopept (omberacetam)

Noopept (omberacetam) at a glance

What is Noopept?

Noopept (omberacetam) structure and chemistry

What Noopept studies show

Brain and nerves

Memory and thinking

Mood, stress and behavior

Cells, genes and aging

Daily life and fitness

Immune system and inflammation

All 5 studies in people

Key Noopept studies

Noopept clinical trials

Is Noopept approved?

Noopept side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about Noopept

Related peptides

Sources